Arcus Biosciences

Arcus Biosciences was a clinical-stage biopharmaceutical company headquartered in Hayward, California, focused on developing novel cancer immunotherapies and inflammatory disease treatments. The company was founded in 2015 by Terry McGuire and Jennifer D. Johnson, building on research from Stanford University.

Overview

Arcus Biosciences was a clinical-stage biopharmaceutical company headquartered in Hayward, California, focused on developing novel cancer immunotherapies and inflammatory disease treatments. The company was founded in 2015 by Terry McGuire and Jennifer D. Johnson, building on research from Stanford University.

Overview

Arcus Biosciences operated with a mission to create differentiated cancer immunotherapies by targeting key pathways in the tumor microenvironment. The company established strategic partnerships with major pharmaceutical companies including Gilead Sciences and Pfizer, leveraging its proprietary technology platform to develop next-generation immunotherapies["@arcusa"].

The company's approach focused on:

• Immune checkpoint inhibition: Targeting novel pathways beyond PD-1
• Adenosine receptor antagonism: Modulating the immunosuppressive adenosine pathway
• CD73 inhibition: Blocking adenosine generation in the tumor microenvironment
• TIGIT blockade: Preventing tumor immune evasion

Funding

• IPO: 2018 (NASDAQ: RCUS)
• Market Cap: ~$2B (2026)

Company History and Development

Founding and Early Growth (2015-2020)

Gilead Partnership and Expansion (2016-2023)

• 2017: Expanded partnership to include additional programs
• 2020: Gilead invested $375 million in Arcus (20% equity)
• 2023: Announced intent to acquire Arcus for $14.6 billion[@gilead]

Acquisition by Gilead Sciences

• Announcement: November 2023
• Closing: March 2024
• Deal Value: Approximately $14.6 billion USD ($58 per share)
• Strategic Rationale: Strengthened Gilead's oncology portfolio with Arcus's innovative immunotherapy pipeline

Pipeline and Programs

Clinical Programs

| Drug Candidate | Target | Indication | Stage |
|---------------|--------|------------|-------|
| Domvanalimab | TIGIT | NSCLC, gastric cancer | Phase 3[@domvanalimab] |
| Zimberelimab | PD-1 | Multiple cancers | Phase 2/3 |
| Etrumadenant | A2a/A2b adenosine receptor | Renal cell carcinoma | Phase 2 |
| Quemliclustat | CD73 | Solid tumors | Phase 1/2 |
| Mupadolimab | CD73 | Solid tumors | Phase 1/2 |

Research Programs

• AB309: Next-generation anti-TIGIT antibody with enhanced effector function
• AB821: Novel immunomodulatory agent targeting innate immunity
• AB308: Immuno-oncology candidate with novel mechanism
• AB680: Hydrolysis-stabile CD73 inhibitor

Science and Technology Platform

Adenosine Pathway Inhibition

Arcus's adenosine receptor antagonists (etrumadenant) block this immunosuppressive signaling, potentially restoring immune cell function.

TIGIT Targeting

Clinical Development Highlights

Domvanalimab (Anti-TIGIT)

• Phase 3 ARION trial: Evaluating domvanalimab + zimberelimab vs. pembrolizumab in first-line NSCLC
• Phase 2 STAR-121 trial: Gastric cancer in combination with chemotherapy
• Mechanism: Fc-enabled anti-TIGIT for enhanced effector function

Etrumadenant (Adenosine Receptor Antagonist)

• Phase 2 ARC-6 trial: Renal cell carcinoma
• Combination: With zimberelimab and chemotherapy
• Biomarker: CD73 expression as predictive marker

Financial Highlights

• Pre-acquisition market cap: Approximately $12 billion USD
• Key investors: OrbiMed, Vivo Capital, Google Ventures (GV), Casdin Capital
• Cash position at acquisition: Approximately $1.7 billion USD

Neurological Relevance

While primarily focused on immuno-oncology, Arcus's adenosine receptor antagonists may have implications for neuroinflammation in brain tumors and potential CNS applications[@cd]:

• Brain tumor immunotherapy: CD73 and adenosine pathway inhibition in glioblastoma
• CNS inflammation: Potential applications in autoimmune encephalitis
• Blood-brain barrier: Research on CNS penetration of immunotherapies
• [Immunotherapy](/therapeutics/immunotherapy)
• Tumor Microenvironment
• [Adenosine Signaling](/genes/gnal)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Gilead Sciences](/companies/gilead)
• [TIGIT Signaling](/genes/gnal)
• CD73
• Glioblastoma
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Arcus Biosciences discovered through SciDEX knowledge graph analysis: